NCT03823534 2026-04-22
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
St. Louis University
Phase 3 Recruiting
Clinical Trials
481 trialsNCT04973605 2026-04-22
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
BeOne Medicines
Phase 1/2 Recruiting
NCT05972135 2026-04-22
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT06679101 2026-04-22
DREAMM-10
GlaxoSmithKline
Phase 3 Recruiting
NCT05646576 2026-04-21
PEACE
Massachusetts General Hospital
Phase NA Recruiting
NCT06622005 2026-04-21
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT01676805 2026-04-20
Tissue Collection for Studies of Lymph Cancer
National Institutes of Health Clinical Center (CC)
Recruiting
NCT03412877 2026-04-20
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03761108 2026-04-20
LINKER-MM1
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT05135351 2026-04-20
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy
University of Nebraska
Phase NA Recruiting
NCT05909059 2026-04-20
CAR T-cell Therapy in Patients With Renal Dysfunction
Northside Hospital, Inc.
Phase 2 Recruiting
NCT05969860 2026-04-20
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
Phase 2 Recruiting
NCT06179888 2026-04-20
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07280013 2026-04-17
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
C4 Therapeutics, Inc.
Phase 1 Recruiting
NCT06057402 2026-04-16
MagnetisMM15
Pfizer
Phase 4 Recruiting
NCT06083922 2026-04-16
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06152575 2026-04-16
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT06385652 2026-04-16
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
Peking University First Hospital
Phase EARLY_PHASE1 Recruiting
NCT06484777 2026-04-16
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT06870760 2026-04-16
Pre-malignant States to Hematologic Malignancies in Firefighters
Wake Forest University Health Sciences
Recruiting
NCT07075185 2026-04-16
inMMyCAR
Kelonia Therapeutics, Inc.
Phase 1 Recruiting
NCT07095452 2026-04-16
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie
Phase 2/3 Recruiting
NCT03710421 2026-04-15
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
City of Hope Medical Center
Phase 1 Recruiting
NCT05336383 2026-04-15
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05623020 2026-04-15
MagnetisMM-6
Pfizer
Phase 3 Recruiting
NCT07107529 2026-04-15
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
European Myeloma Network B.V.
Phase 2 Recruiting
NCT07455851 2026-04-15
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT00900198 2026-04-14
Collection of Tissue Samples for Cancer Research
National Institutes of Health Clinical Center (CC)
Recruiting
NCT02682667 2026-04-14
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
National Institutes of Health Clinical Center (CC)
Recruiting
NCT06103838 2026-04-14
18F-Fluciclovine PET/CT in Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06182774 2026-04-14
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT06615479 2026-04-14
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT07030517 2026-04-14
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
Johnson & Johnson Private Limited
Phase 4 Recruiting
NCT07382739 2026-04-14
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07409246 2026-04-14
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
AbbVie
Phase 1 Recruiting
NCT07529782 2026-04-14
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT01890486 2026-04-13
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Wake Forest University Health Sciences
Recruiting
NCT03017820 2026-04-13
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT04634552 2026-04-13
MonumenTAL-1
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT05160584 2026-04-13
MoMMent
Janssen Pharmaceutica N.V., Belgium
Recruiting
NCT05201781 2026-04-13
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Janssen Research & Development, LLC
Phase 4 Recruiting
NCT05438043 2026-04-13
A Study of Daratumumab
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05552222 2026-04-13
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05652335 2026-04-13
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06145581 2026-04-13
Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
Mayo Clinic
Phase NA Recruiting
NCT06285318 2026-04-13
REALiTEC/TAL
Janssen-Cilag Ltd.
Recruiting
NCT06433947 2026-04-13
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Opna Bio LLC
Phase 1 Recruiting
NCT06465316 2026-04-13
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06483100 2026-04-13
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Washington University School of Medicine
Phase 2 Recruiting
NCT06500884 2026-04-13
Talisman
Janssen Research & Development, LLC
Phase 2 Recruiting